Request Trial
shutterstock_1117001510_angelsolergollonet
angelsolergollonet / Shutterstock.com
12 February 2019Pharma

UK could lose out on Europe-wide drug safety system post-Brexit

UK patients could be more exposed to counterfeit medicines than EU patients in the event of a ‘no deal’ Brexit, because access to an initiative aimed at protecting patients from fake drugs could be lost.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Non-profit sues Cambrex over anticancer drug manufacturing trade secrets
17 September 2026   Bauer Research Foundation has alleged that the CDMO misappropriated its confidential manufacturing know-how related to NO-Cbl, an anticancer drug candidate in the pre-clinical/translational stage of development for potential human use.
Pharma
Beyond the primary patent: How pharma can build competitive barriers
16 September 2026   A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.
Pharma
J&J unit win shuts door on Sandoz generic launch
10 September 2026   Four patents stood firm in a Johnson & Johnson unit’s fight with Sandoz, leaving the generics maker facing a lengthy wait before its esketamine nasal spray can reach the US market.


Editor's picks

Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

Editor's picks

Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026
Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026
Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
25 August 2026
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026

More features

Leading European patent litigator to join Carpmaels & Ransford
CIPA Congress: Sustainability is essential for the profession and the planet
Non-profit sues Cambrex over anticancer drug manufacturing trade secrets
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Amgen hit with lawsuit over its proposed Opdivo biosimilar
Beyond the primary patent: How pharma can build competitive barriers
Australian biotech sues Grail over multi-cancer blood test
K&L Gates hires six-strong team of IP and corporate lawyers from Pillsbury